Mizuho Cuts Boston Scientific (NYSE:BSX) Price Target to $115.00

Boston Scientific (NYSE:BSX) had its target price reduced by Mizuho from $140.00 to $115.00 in a report released on Thursday morning, MarketBeat.com reports. They currently have an outperform rating on the medical equipment provider’s stock.

Several other research analysts also recently commented on the stock. Truist Financial lowered their price objective on shares of Boston Scientific from $130.00 to $120.00 and set a “buy” rating for the company in a research report on Thursday, December 18th. Canaccord Genuity Group lowered their price target on Boston Scientific from $132.00 to $131.00 and set a “buy” rating for the company in a report on Wednesday, December 17th. Barclays dropped their price objective on Boston Scientific from $136.00 to $124.00 and set an “overweight” rating for the company in a research report on Tuesday. Citigroup decreased their target price on Boston Scientific from $130.00 to $102.00 and set a “buy” rating on the stock in a research report on Thursday. Finally, Oppenheimer lowered their target price on Boston Scientific from $125.00 to $100.00 and set an “outperform” rating for the company in a research note on Friday, January 16th. One investment analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $109.43.

Boston Scientific Stock Down 1.8%

Shares of NYSE BSX opened at $76.24 on Thursday. The stock has a market capitalization of $113.02 billion, a P/E ratio of 39.30, a PEG ratio of 1.35 and a beta of 0.67. The stock’s fifty day moving average is $93.39 and its 200 day moving average is $98.75. Boston Scientific has a 52 week low of $74.86 and a 52 week high of $109.50. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings data on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.78 by $0.02. The firm had revenue of $5.29 billion for the quarter, compared to the consensus estimate of $5.29 billion. Boston Scientific had a net margin of 14.44% and a return on equity of 19.96%. The business’s revenue for the quarter was up 15.9% on a year-over-year basis. During the same period in the prior year, the company posted $0.70 earnings per share. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. Sell-side analysts forecast that Boston Scientific will post 2.85 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Boston Scientific news, CEO Michael F. Mahoney sold 160,901 shares of Boston Scientific stock in a transaction dated Monday, February 2nd. The stock was sold at an average price of $93.49, for a total transaction of $15,042,634.49. Following the transaction, the chief executive officer directly owned 1,411,735 shares of the company’s stock, valued at approximately $131,983,105.15. The trade was a 10.23% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Arthur C. Butcher sold 17,313 shares of the stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $101.55, for a total value of $1,758,135.15. Following the completion of the sale, the executive vice president directly owned 23,600 shares of the company’s stock, valued at approximately $2,396,580. The trade was a 42.32% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.50% of the stock is currently owned by insiders.

Institutional Trading of Boston Scientific

Several institutional investors have recently added to or reduced their stakes in the stock. State Street Corp grew its stake in Boston Scientific by 1.1% in the 2nd quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock valued at $7,002,258,000 after purchasing an additional 713,379 shares during the period. Synergy Asset Management LLC boosted its holdings in shares of Boston Scientific by 3,493.0% in the 3rd quarter. Synergy Asset Management LLC now owns 493,323 shares of the medical equipment provider’s stock worth $48,297,000 after buying an additional 479,593 shares during the last quarter. Gladstone Institutional Advisory LLC grew its position in Boston Scientific by 39.5% during the third quarter. Gladstone Institutional Advisory LLC now owns 51,884 shares of the medical equipment provider’s stock valued at $5,065,000 after buying an additional 14,700 shares during the period. Channel Wealth LLC increased its holdings in Boston Scientific by 70.8% during the third quarter. Channel Wealth LLC now owns 28,577 shares of the medical equipment provider’s stock worth $2,790,000 after buying an additional 11,847 shares during the last quarter. Finally, Bank of Nova Scotia raised its position in Boston Scientific by 106.4% in the second quarter. Bank of Nova Scotia now owns 3,025,519 shares of the medical equipment provider’s stock worth $324,971,000 after acquiring an additional 1,559,605 shares during the period. 89.07% of the stock is currently owned by institutional investors.

Key Boston Scientific News

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Q4 beat but mixed outlook — Boston Scientific reported stronger-than-expected Q4 results (revenue growth and EPS beat), showing continued top-line momentum that supports the longer‑term growth story. Q4 results and presentation
• Positive Sentiment: Some analysts still rate BSX as a buy/overweight with mid‑to‑high price targets — several firms left positive ratings (Morgan Stanley set a $118 PT; others keep “outperform/overweight”), indicating continued analyst confidence in long-term upside despite near-term caution. Morgan Stanley PT note
• Neutral Sentiment: Board change announced — Boston Scientific disclosed a planned long‑serving director departure; governance turnover is notable but not currently flagged as material to near‑term operations. Board director departure
• Neutral Sentiment: Unusually active options and volume — options and share volume spiked during the sell‑off, increasing volatility and making short-term price moves more extreme (can amplify both down and up moves). Options activity
• Negative Sentiment: Cautious 2026 guidance and weak electrophysiology sales drove a sharp sell‑off — management’s conservative revenue/growth guidance and softer performance in a key segment prompted a high‑volume liquidation that erased recent gains. Guidance and segment weakness
• Negative Sentiment: Multiple securities‑fraud investigations announced — several law firms have opened inquiries into Boston Scientific’s disclosures around the quarter/guidance, increasing legal and reputational risk. Howard G. Smith investigation Frank R. Cruz investigation
• Negative Sentiment: Insider selling and new lows — CEO share sales and headlines about insider selling coincided with the stock reaching a 12‑month low, which can undermine investor confidence even when fundamentals are mixed. CEO stock sale note 12-month low report
• Negative Sentiment: Widespread analyst price‑target cuts — multiple firms trimmed their 12‑month targets after Q4/guidance, increasing short‑term downside pressure even where ratings remain constructive. Analyst cuts roundup

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.